Poniard Pharmaceuticals, Inc.
PARD · OTC
12/31/2010 | 12/31/2009 | 12/31/2008 | 12/31/2007 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.20 | -0.01 | 0.05 |
| FCF Yield | -99.65% | -55.02% | -202.43% | -89.71% |
| EV / EBITDA | -0.99 | -1.77 | 0.04 | -0.52 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 0.00% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.81 | 0.78 | 0.69 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 31.62% | -4.82% | -11.35% | -34.28% |
| Safety | ||||
| Net Debt / EBITDA | -0.01 | -0.11 | 0.39 | 0.63 |
| Interest Coverage | -12.65 | -13.67 | -25.91 | -20.47 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -137.53 | 0.00 |